InsiderClue
Stocks · Health care · Wholesale-Drugs, Proprietaries & Druggists' Sundries

Cellyan Biotechnology Co., Ltd

HKPD Clue Score41
Cayman Islands Fiscal year ends March CIK 0002007702
$0.11 -4.82% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.11 −91.47% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 15 Jan 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue12.6Operating income−1.8Net income1.0EPS, diluted0.15Fiscal year 2024Revenue16.7 +32.9%Operating income−2.0Net income1.3 +33.2%EPS, diluted0.18 +23.3%Fiscal year 2025Revenue20.3 +21.7%Operating income−2.3Net income−0.0 −102.0%EPS, diluted−0.00 −101.7%
FY2023FY2024FY2025
Revenue 12.6 16.7 20.3
Growth +32.9% +21.7%
Operating income −1.8 −2.0 −2.3
Net income 1.0 1.3 −0.0
Growth +33.2% −102.0%
EPS, diluted 0.15 0.18 −0.00
Growth +23.3% −101.7%

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2023Gross margin21.8%Operating margin−14.3%Net margin7.9%Free cash flow margin12.8%Fiscal year 2024Gross margin21.3%Operating margin−11.7%Net margin8.0%Free cash flow margin−2.7%Fiscal year 2025Gross margin11.9%Operating margin−11.2%Net margin−0.1%Free cash flow margin2.5%
FY2023FY2024FY2025
Gross margin 21.8% 21.3% 11.9%
Operating margin −14.3% −11.7% −11.2%
Net margin 7.9% 8.0% −0.1%
Free cash flow margin 12.8% −2.7% 2.5%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow1.7Capital expenditure−0.1Free cash flow1.6Fiscal year 2024Operating cash flow−0.4Capital expenditure−0.1Free cash flow−0.4 −127.7%Fiscal year 2025Operating cash flow0.6Capital expenditure−0.1Free cash flow0.5
FY2023FY2024FY2025
Operating cash flow 1.7 −0.4 0.6
Capital expenditure −0.1 −0.1 −0.1
Free cash flow 1.6 −0.4 0.5
Growth −127.7%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash and securitiesTotal debt
Fiscal year 2023Shareholders’ equity0.6Fiscal year 2024Cash and securities0.6Total debt1.3Net cash (debt)−0.7Shareholders’ equity4.3Debt to equity0.31Fiscal year 2025Cash and securities0.7Total debt1.9Net cash (debt)−1.1Shareholders’ equity5.0Debt to equity0.38
FY2023FY2024FY2025
Cash and securities n/a 0.6 0.7
Total debt n/a 1.3 1.9
Net cash (debt) n/a −0.7 −1.1
Shareholders’ equity 0.6 4.3 5.0
Debt to equity n/a 0.31 0.38

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending March, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Mar 2023 FY2024 31 Mar 2024 FY2025 31 Mar 2025
Revenue and profit
12.6 16.7 20.3
Growth +32.9% +21.7%
9.8 13.1 17.9
2.7 3.6 2.4
Growth +29.9% −32.1%
1.8 1.9 2.2
−1.8 −2.0 −2.3
Growth
1.0 1.5 0.0
0.0 0.2 0.1
1.0 1.3 −0.0
Growth +33.2% −102.0%
Per share
0.15 0.18 −0.00
0.15 0.18 −0.00
Growth +23.3% −101.7%
6.8 7.4 10.2
6.8 7.4 10.2
Growth +7.6% +38.6%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 1 of 3 years on file.